Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan Bielack(Olgahospital), Mark L. Bernstein(University of Louisville), Reinhard Windhager(Medical University of Vienna), Carol D. Morris(Memorial Sloan Kettering Cancer Center), Joachim Gerß, Pancras C.W. Hogendoorn(Vrije Universiteit Brussel), Beatrice Seddon(University College London Hospitals NHS Foundation Trust), Trude Butterfaß‐Bahloul(University Hospital Münster), Susan Picton(Helios Klinikum Emil von Behring), Henk van den Berg(Emma Kinderziekenhuis), Paul A. Meyers(Memorial Sloan Kettering Cancer Center), Helen Nadel(Helios Klinikum Emil von Behring), Daniel Baumhoer(University Hospital of Basel), Per‐Ulf Tunn(Helios Klinikum Emil von Behring), Gordana Jovic(MRC Clinical Trials Unit at UCL), Gabriele Calaminus(University Hospital Bonn), Hans Gelderblom(Leiden University Medical Center), K. Helmke(Universität Hamburg), Catharina Dhooge(Ghent University Hospital), Richard Görlick(The University of Texas MD Anderson Cancer Center), Mikael Eriksson(Herlev Hospital), Peter Reichardt(Helios Hospital Berlin-Buch), Mathias Werner(Helios Klinikum Emil von Behring), Tom Böhling(University of Helsinki), Jeremy Whelan(University College London Hospitals NHS Foundation Trust), Allen M. Goorin(Dana-Farber Cancer Institute), R. Lor Randall(University of California Davis Medical Center), Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Bernadette Brennan(Royal Manchester Children's Hospital), Claudia Deffenbaugh(Helios Klinikum Emil von Behring), Zsuzsanna Pápai(National Institute of Oncology), G. Douglas Letson(Moffitt Cancer Center), Sigbjørn Smeland(Oslo University Hospital), Mark C. Gebhardt(Boston Children's Hospital), Neyssa Marina(Coherus BioSciences (United States)), Rajaram Nagarajan(University of Minnesota), Peter M. Hoogerbrugge(Helios Klinikum Emil von Behring), Kirsten Sundby Hall(Oslo University Hospital), Mark Krailo(Arcadia), James S. Meyer(Helios Klinikum Emil von Behring), Thomas Kühne(University Children’s Hospital Basel), Marleen Renard, Ching C. Lau(Helios Klinikum Emil von Behring), Heribert Jürgens(University Hospital Münster), Jane Hook(University of Leeds), Maria Michelagnoli(Helios Klinikum Emil von Behring), Leo Kager(University of Vienna), Paula J. Schomberg(WinnMed), Lisa A. Teot(Boston Children's Hospital)
Cited by 419
Related Papers
Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k